The oncogenic role of NOTCH1 as biomarker in oral squamous cell carcinoma and oral lichen planus.
Biomarkers
NOTCH1
oncogenes
oral lichen planus
squamous cell carcinoma of head and neck
Journal
Dental research journal
ISSN: 1735-3327
Titre abrégé: Dent Res J (Isfahan)
Pays: Iran
ID NLM: 101471186
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
11
2022
revised:
19
03
2023
accepted:
03
07
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Oral squamous cell carcinoma (OSCC) is the most common type of oral cancer with heterogeneous molecular pathogenesis. Oral lichen planus (OLP) is demonstrated potentially can transfer to OSCC malignant lesions. Unfortunately, there are no definitive prognostic and predictive biomarkers for the clinical management of OSCC patients. The present research is the first study that compared an oral premalignant lesion such as OLP to malignant lesions like OSCC for NOTCH1 expression levels to better understand its oncogenic or tumor suppressive role. In this cross-sectional study, mRNA expression of NOTCH1 was evaluated by quantitative polymerase chain reaction in 65 tissue-embedded Paraffin-Block samples, including 32 OSCC and 33 OLP. Furthermore, we collected demographic information and pathological data, including tumor stage and grade. The association between NOTCH1 and GAPDH gene expressions was determined by Chi-squared, Spearman, and Mann-Whitney tests. A Comparison of OSCC and OLP groups showed a statistically significant difference between the quantitative expression of the NOTCH1 gene ( Since the OSCC is a malignant lesion and the OLP showed the possible nature of malignancy transformation, we can consider the NOTCH1 as a biomarker for the assessment of the tumorigenesis process with a definition of a standard threshold for potentially malignant lesions and malignant OSCC tumors.
Sections du résumé
Background
UNASSIGNED
Oral squamous cell carcinoma (OSCC) is the most common type of oral cancer with heterogeneous molecular pathogenesis. Oral lichen planus (OLP) is demonstrated potentially can transfer to OSCC malignant lesions. Unfortunately, there are no definitive prognostic and predictive biomarkers for the clinical management of OSCC patients. The present research is the first study that compared an oral premalignant lesion such as OLP to malignant lesions like OSCC for NOTCH1 expression levels to better understand its oncogenic or tumor suppressive role.
Materials and Methods
UNASSIGNED
In this cross-sectional study, mRNA expression of NOTCH1 was evaluated by quantitative polymerase chain reaction in 65 tissue-embedded Paraffin-Block samples, including 32 OSCC and 33 OLP. Furthermore, we collected demographic information and pathological data, including tumor stage and grade. The association between NOTCH1 and GAPDH gene expressions was determined by Chi-squared, Spearman, and Mann-Whitney tests. A
Results
UNASSIGNED
Comparison of OSCC and OLP groups showed a statistically significant difference between the quantitative expression of the NOTCH1 gene (
Conclusion
UNASSIGNED
Since the OSCC is a malignant lesion and the OLP showed the possible nature of malignancy transformation, we can consider the NOTCH1 as a biomarker for the assessment of the tumorigenesis process with a definition of a standard threshold for potentially malignant lesions and malignant OSCC tumors.
Types de publication
Journal Article
Langues
eng
Pagination
102Informations de copyright
Copyright: © 2023 Dental Research Journal.
Déclaration de conflit d'intérêts
The authors of this manuscript declare that they have no conflicts of interest, real or perceived, financial or nonfinancial in this article.
Références
Indian J Dermatol. 2015 May-Jun;60(3):222-9
pubmed: 26120146
Cancers (Basel). 2021 Jun 21;13(12):
pubmed: 34205690
Rep Biochem Mol Biol. 2020 Jul;9(2):171-179
pubmed: 33178866
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Biomed Res Int. 2020 Jul 17;2020:8573793
pubmed: 32733958
J Hepatol. 2021 Mar;74(3):613-626
pubmed: 33038431
Cancer Metastasis Rev. 2022 Sep;41(3):737-747
pubmed: 35624227
Arch Dermatol Res. 2016 Oct;308(8):539-51
pubmed: 27349424
Int J Oncol. 2010 Apr;36(4):817-22
pubmed: 20198324
Oncol Rep. 2018 Jun;39(6):2584-2594
pubmed: 29620248
J Dent Res. 2018 Jun;97(6):645-653
pubmed: 29489439
Toxicol Appl Pharmacol. 2022 Apr 1;440:115951
pubmed: 35235860
Lancet. 2021 Dec 18;398(10318):2289-2299
pubmed: 34562395
Clin Cancer Res. 2018 Dec 15;24(24):6308-6318
pubmed: 30087145
Biosci Rep. 2021 Sep 30;41(9):
pubmed: 34402503
Cancer Cell Int. 2018 Jan 08;18:6
pubmed: 29321718
F1000Res. 2020 Apr 2;9:229
pubmed: 32399208
J Cell Physiol. 2019 May;234(5):5940-5952
pubmed: 30515785
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Oral Oncol. 2020 Nov;110:105003
pubmed: 32932170
Anticancer Agents Med Chem. 2019;19(17):2072-2078
pubmed: 31660843
PLoS One. 2018 Jul 12;13(7):e0200619
pubmed: 30001383
Mol Biol Rep. 2021 Apr;48(4):3617-3628
pubmed: 33822294
Nat Commun. 2020 Nov 9;11(1):5671
pubmed: 33168804
Adv Exp Med Biol. 2021;1287:183-200
pubmed: 33034033
Biomed Pharmacother. 2020 Sep;129:110416
pubmed: 32593969
Front Oncol. 2021 May 31;11:660696
pubmed: 34136393
J Oncol. 2021 Feb 13;2021:6663720
pubmed: 33854547
Int J Mol Sci. 2019 Mar 26;20(6):
pubmed: 30917608
CMAJ. 2020 Aug 4;192(31):E892
pubmed: 32753462
Metabolomics. 2020 Sep 30;16(10):105
pubmed: 33000429
Gastroenterology. 2020 Aug;159(2):575-590
pubmed: 32325086
Iran J Otorhinolaryngol. 2018 Sep;30(100):261-271
pubmed: 30245980
Health Sci Rep. 2022 Nov 06;5(6):e921
pubmed: 36381409